Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198039 | 0.88 | ALDH1A1 (0.65) | ALDH1A1KDM4EHPGDRCE1TDP1 | |
| SCHEMBL4629157 | 0.86 | KDM4E (0.67) | ALDH1A1KDM4ETDP1CHRM2BCHE | |
| SCHEMBL3220995 | 0.81 | HTR2A (0.44) | ALDH1A1KDM4ECYP3A4CYP2D6GAA | |
| SCHEMBL2129001 | 0.78 | TSHR (0.52) | ALDH1A1KDM4EHPGDRCE1CHRM2 | |
| SCHEMBL5695121 | 0.77 | ALDH1A1 (0.79) | ALDH1A1KDM4ETDP1CHRM2BCHE | |
| SCHEMBL3197983 | 0.75 | ALDH1A1 (0.57) | ALDH1A1KDM4ETDP1CYP3A4CYP2D6 | |
| SCHEMBL2782788 | 0.73 | ALDH1A1 (0.58) | ALDH1A1KDM4ETDP1CHRM2BCHE | |
| SCHEMBL22716808 | 0.73 | HTT (0.50) | TDP1CHRM2BCHEGRIN1GRIN2A | |
| SCHEMBL10388544 | 0.72 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDRCE1ADRA2B | |
| SCHEMBL7000552 | 0.72 | KDM4E (0.69) | ALDH1A1KDM4ETDP1BCHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-1917245-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007022946-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | ALDH1A1 1897/4885KDM4E 3028/4885HPGD 1244/4885 |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | ALDH1A1 1897/4885KDM4E 3028/4885HPGD 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.